Daniel Pereira Monteiro: Why Is Beta Thalassaemia Major so Severe?
Daniel Pereira Monteiro, Founder and Education Lead of Haemopaedia, Screening Professional Scientific Advisor at NHS England, shared a post on LinkedIn:
“We know that beta thalassaemia major is a severe condition… but do you know why?
Let’s test your haemoglobinopathy interpretation skills
Would you like to know:
- What is beta thalassaemia major?
- What causes it?
- What happens physiologically to try to compensate?
- How would you spot it in the laboratory?
Welcome to Haemopaedia Case of the Week
This case counts towards your monthly CPD Certificate!
You are free to participate, here is how:
- Submit your answer via the Haemopaedia form available in the comment section
- Drop your interpretation also in the comments below
Both steps are required for CPD recognition
Want to know about upcoming training sessions, webinars and case-based learning every week, straight to your email?
Signing up to Haemopaedia’s LabLines Newsletter.
But you are free to unsubscribe at any time.
Have a case you’d like featured?
DM me to share an anonymised example for future posts.
I’m Daniel Monteiro.
I help students and healthcare professionals, including biomedical scientists, nurses, and doctors, to master the complexities of hemoglobinopathy screening and diagnosis through evidence-based guidance and real-world case studies.
I founded Haemopaedia to provide scientifically rigorous training material for everyone, from laboratory scientists to clinicians looking to deepen their understanding of hemoglobinopathies or who simply like to have a diagnostic challenge
Disclaimer:
All cases shared in these series are for educational purposes only and do not constitute clinical or diagnostic advice.
Contributors are reminded to make sure all examples are fully anonymised and shared in accordance with their local governance and confidentiality policies.”
Other posts featuring Daniel Pereira Monteiro on Hemostasis Today.
-
Nov 9, 2026, 13:48PF4-ELISA–Negative HIT: Are We Missing a New Class of Anti-PF4 Immunothrombotic Disease?
-
Nov 9, 2026, 13:07Nandini Sadasivam: Gene Therapy for Sickle Cell Disease and Thalassaemia
-
Nov 9, 2026, 13:04Raising Awareness of Bleeding Disorders in Women and Girls – EHC
-
Nov 9, 2026, 12:59Rahul Bohra: Exploring the Complex Mechanisms of Sickle Cell Disease
-
Nov 9, 2026, 12:53Three Years of Movement and Thrombosis Awareness in the Czech Republic – World Thrombosis day
-
Nov 9, 2026, 12:51Octavio Marques Pontes-Neto: Intensive Blood-Pressure Control Reduces Cardiovascular Events After Ischemic Stroke
-
Nov 9, 2026, 12:49Irma Bagdoniene: What Really Makes Us Live Longer
-
Nov 9, 2026, 12:47Imo Akpan: Announcing the 2027 Women’s Hematology Summit
-
Nov 9, 2026, 12:45Shadi Yaghi: Rethinking Antithrombotic Therapy After Stroke